secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIxCrypto Holdings, Inc. (AIXC)
CIK:        0001460702
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001493152-24-042068
Event type: regulatory
Sentiment:  negative
Materiality: 0.45
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Qualigen Therapeutics receives Nasdaq non-compliance notice for audit committee composition
--------------------------------------------------------------------------------

- Notice received Oct 18, 2024, after director Matt Korenberg resigned from Board and Audit Committee effective Oct 3, 2024.
- Audit Committee now has only two independent directors (Robert Lim, Cody Price); needs three per Nasdaq Rule 5605.
- Cure period: earlier of next annual meeting or Oct 5, 2025; if meeting before Apr 1, 2025, compliance due by Apr 1, 2025.
- Company plans to appoint one independent director to Audit Committee during the cure period.
- No immediate effect on listing or trading of QLGN common stock on The Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1460702/000149315224042068/0001493152-24-042068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1460702/000149315224042068/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer